Glucocorticoid receptor antagonists for treatment of diabetes

US6593480B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Philip R. Kym · Libertyville, US
• Benjamin C. Lane · Libertyville, US
• John K. Pratt · Kenosha, US
• Tom von Geldern · Richmond, US
• Martin Winn · Deerfield, US
• Jehrod Burnett Brenneman · Southbury, US
• Jyoti R. Patel · Libertyville, US
• David L. Arendsen · Libertyville, US
• Irini Akritopoulou-Zanze · Libertyville, US
• Kimba L. Ashworth · Gurnee, US
• Kresna Hartandi · Los Angeles, US

Key dates

• Filing date: Feb 28, 2001
• Grant date: Jul 15, 2003
• Expiry date: Sep 7, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of formula I are useful for treating type II diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.